Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya

This is a replication dataset for the manuscript titled: \"Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.\". This is a dataset summarising demographic, hepatitis B test results and alanine aminotransferase data from 6 completed different clinical trials conducted at KEMRI-Wellcome Trust Research Programme since 2016. The aim of this work was to give a seroprevalence estimate for HBV in Kilifi and also illustrate the amount of data that is likely available in this space that is currently underutilised. Data were accessed with permission from study PIs and from sponsors where necessary. These data were standardised for age and sex using the Kilifi health and demographic surveillance system (KHDSS) data as the standard population structure. This data showed a crude HBsAg seroprevalence rate of 3.5%, which rose to 5% when standardised. There was considerable underrepresentation of women in these trials with 77% of participants being male. ALT was significantly higher in those who were HBsAg positive compared to negative, although was not outside the upper limit of normal for this population. We argue from these results that routine collection and collation of both blood borne virus prevalence and liver function test information will enable better modelling of not only blood borne viruses, but also for estimating the burden from liver disease across the African region. This would be a low cost, efficient method that negates the need for the organisation of large sero-epidemiological surveys

本数据集为下述学术论文的复现数据集：《数据去向何方？复用肯尼亚基利菲地区成人乙型肝炎病毒（HBV）感染人群患病率的临床试验筛查结果》。本数据集汇总了2016年以来，在肯尼亚医学研究所-威康信托研究项目（KEMRI-Wellcome Trust Research Programme）开展的6项已完成的独立临床试验的人口统计学特征、乙型肝炎检测结果及丙氨酸氨基转移酶（alanine aminotransferase, ALT）数据。本研究旨在估算基利菲地区HBV的血清流行率，同时阐明当前该领域尚未被充分利用的潜在可用数据规模。数据获取已获得各试验项目主要研究者（Principal Investigators, PIs）的许可，必要时还获得了资助方的授权。本数据集以基利菲健康与人口监测系统（KHDSS）的人口结构为参照，对数据按年龄与性别进行了标准化校正。数据显示，未校正的乙型肝炎表面抗原（hepatitis B surface antigen, HBsAg）血清流行率为3.5%，经标准化校正后升至5%。上述临床试验中女性受试者占比显著偏低，男性参与者占比达77%。HBsAg阳性受试者的ALT水平显著高于阴性受试者，但仍处于该人群的正常参考值上限范围内。基于上述研究结果，本研究认为，常规收集并整合血源性病毒流行率与肝功能检测相关信息，不仅可优化血源性病毒的建模分析，还能用于估算整个非洲地区的肝脏疾病负担。该方法成本低廉、高效可行，无需组织大规模血清流行病学调查。